![Bio Synex Logo](https://chembio.com/wp-content/uploads/2023/04/Biosynex-Newsroom-1920x1080-1-600x403.png)
Chembio Diagnostics, Inc. becomes the first North American structure controlled by Biosynex in North America STRASBOURG, France, April 27, 2023 (GLOBE NEWSWIRE) -- Biosynex SA (“Biosynex”) (EPA: ALBIO), a French market…
![](https://chembio.com/wp-content/uploads/2022/11/CLIA-submission-2-600x403.jpg)
MEDFORD, N.Y., Feb. 24, 2023 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced receipt of a Clinical Laboratory Improvement Amendments (CLIA) waiver from the U.S.…
![Treponema Pallidum Spyrochete](https://chembio.com/wp-content/uploads/2022/11/chembio-post-bg-600x403.jpg)
HAUPPAUGE, N.Y., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Chembio) (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced it was awarded a $3.2 million contract from the Centers for Disease Control…